author-photo

Barbara Klencke

The Chinese University of Hong Kong

16

Papers

745

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Poster: MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
MPN-149: Long-Term Safety of Momelotinib in JAK Inhibitor-Naïve and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients

2020 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials

2017 Drug Design Development and Therapy
Show All
- Source
- Cite
- Save
Citations (36)
A phase I study of oral SRA737 (formerly CCT245737) given in combination with gemcitabine plus cisplatin or gemcitabine alone in patients with advanced cancer.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)